Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Mutant Solid Tumors”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Early research (Phase 1)Ended earlyNCT02703571
What this trial is testing

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Who this might be right for
Solid Tumors for Phase IbPancreatic Cancer for Phase IIColorectal Cancer for Phase II
Novartis Pharmaceuticals 95
Early research (Phase 1)Looking for participantsNCT07134998
What this trial is testing

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 153
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Testing effectiveness (Phase 2)Looking for participantsNCT07148128
What this trial is testing

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who this might be right for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more
Auricula Biosciences Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Early research (Phase 1)Study completedNCT01986166
What this trial is testing

MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Who this might be right for
Neoplasms
Genentech, Inc. 23
Early research (Phase 1)Study completedNCT06235983
What this trial is testing

LY3537982 in Chinese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435455
What this trial is testing

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 126
Early research (Phase 1)Study completedNCT00955773
What this trial is testing

The GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Who this might be right for
Cancer
GlaxoSmithKline 64
Testing effectiveness (Phase 2)Looking for participantsNCT07209111
What this trial is testing

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Who this might be right for
Neoplasm Malignant
Merck Sharp & Dohme LLC 150
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Early research (Phase 1)Study completedNCT02022982
What this trial is testing

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Who this might be right for
KRAS Mutant Non-Small Cell Lung CancerSolid Tumors
Dana-Farber Cancer Institute 60
Testing effectiveness (Phase 2)Looking for participantsNCT06500676
What this trial is testing

GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Who this might be right for
KRAS G12D MutationsAdvanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc. 407
Early research (Phase 1)Active Not RecruitingNCT05631899
What this trial is testing

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Who this might be right for
Solid Tumor, AdultEphA2 OverexpressionKRAS G12V+2 more
Chinese PLA General Hospital 9
Early research (Phase 1)Ended earlyNCT03948763
What this trial is testing

MRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Who this might be right for
NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms+1 more
Merck Sharp & Dohme LLC 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT05358249
What this trial is testing

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung+8 more
Novartis Pharmaceuticals 74
Testing effectiveness (Phase 2)Ended earlyNCT05071183
What this trial is testing

Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Who this might be right for
KRAS Mutation-Related TumorsMetastatic Solid TumorAdvanced Solid Tumor
Turning Point Therapeutics, Inc. 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385678
What this trial is testing

HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 47
Load More Results
110